Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
It might be worth a little recap as to what this company (GDR) actually does & produces - maybe more so for newer investors.
The main product Genedrive (the company) sells is a hand held (Point Of Care - POC) molecular diagnostic device (PCR), confusingly also called a Genedrive.
This device is multi-configurable and works with a series of different tests (or assays). The Genedrive device itself is ready for global use. The assays are individually certified.
The assays currently are:
* The HCV (hepatitis) assay is now on the market globally. It has WHO and CE certs.
* The DOD assays mentioned here were specifically design for the USA forces and (at the moment) for them only and trialled/certified as such.
* The AIHL 'hearing test' is now CE marked, NHS trialled and is soon to hit the UK/Euro market.
* Both swab and saliva SARs (Covid) assays are in development - news is due.
*TB test is also in development.
Separately from the Genedrive device, the company has also developed a lab based assay in the form of a dry pellet for SARs Covid. This has been developed in collaboration with Cytvia. This is also sold with supporting software. This is the test DIVOC and Beckman are interested in.
GDR are also looking at using this assay format for future Genedrive unit tests.
So, GDR is far from a 'Covid play' only.
(Please feel free to correct me if I'm wrong!)
HCV test is not the hearing test.
# I note that
I nite that the leader of the PALOH study, John McDermott, Tweeted yesterday that the final results of the study should be published in time for the European Society of Human Genetics (ESHG) conference on the 28-31 Aug.
Good news and a good launch platform.
https://twitter.com/John_H_McD/status/1405458386339180550?s=19
@Fingeronthepulse
You are correct except it's only a partial buyback.
We bought 60% of an existing royalty and Lith Am have the option for a partial buyback of our % for $13.2M.
This has been known from the start.
With all this persistent pessimism and in-squabbling around I decided to speak to a reliable source, Achilles the deaf Russian Euro 2020 predicting psychic cat. Yep he's real...
https://www.google.com/amp/s/uk.news.yahoo.com/amphtml/psychic-cat-predicts-euro-2020-123507203.html
Now, obviously he didn't hear me (being deaf 'an all), but through his power of thought transference (coupled with my feeble mind), he has reliably informed me that by the end of June POC SARs assay will be CE marked, BC would have sold over $8M with DIVOC over £2M and AIHL pre-orders will be over £12M.
DYOR (I did and it only cost me a packet of Dreamies)
^ ^
oo
»?«
U
GLA.
I must admit GDR sales figures thus far have be moving about as fast as a sedated snail but despite that I still think we've far too many fantastic products to be a total failure and will hopefully come good sooner rather than later.
I'm still adding in little drips just to bring my average down to below a £.
I think PinkInc's Sangentia posting demonstrates that the company is still moving forward. I know the TB assay research has been around for a few years now but it does show the company's tenacity - certainly on the research side and product development side anyways.
My old bones still whisper to me that GDR is prime to snapped up once one or two product sales do take off. I'm think AIHL and HCV.
Would be interesting to know what other assays they're developing alongside TB.
"Patience is bitter, but its fruit is sweet."
- Jean-Jacques Rousseau.
I think our fruit is nearly fossilised! lol.
Here's a small snippet from an article in today's 'Genomics Ad Infinitum Times' in the USA.....
'Today saw the surprise launch from Gen*drive of the the new SAR cas 1SM detection assay for their portable platform. The assay has received full Emergency Approval from Nvr Nvr Land labs has been fully tested using several well known bulletin boards.
The assay scored 95% Non-specificity and 90% Inaccuracy in RNS detection tests.
A company spokesman said "we're extremely excited about this launch and think this assay should be a real seller. It should help many many company executives across the globe when they read investor's comments on bulletin boards".
Share price dropped another 2% on the news'
;)
Could the BOD be buying MIC's shares as part of SOA2.0 or would they have to declare that type of purchase with an RNS?
@MrIndia
"Expectations are too high"
Our expectations are driven by the company's own spoken expectations - check this out from this time last year .
https://www.google.com/amp/s/www.proactiveinvestors.co.uk/companies/amp/news/920677
June sales (2020), POC version later this year (2020) etc.etc.
If the SARs POC is proving temperamental due to its assay's 'wet' components then they may well look to push the holy grail beaded version forward.
Now along with AIHL that would be a double whammy launch this summer! Pow,pow!! lol.
@ Trickymatters
The HCV kit received WHO prequalification last year 4/5/20 RNS.
"the Genedrive® HCV ID kit will be included in the WHO list of prequalified in vitro diagnostics (IVDs) and becomes eligible to participate in the procurement processes of UN agencies. WHO Member States are encouraged to use the WHO list of prequalified IVDs for their respective procurement decisions"
It's currently distributed by Sysmex I believe.
https://extranet.who.int/pqweb/in-vitro-diagnostics
I'm more interested in the AIHL. This is the golden bullet for the appalling prospect of parents having to chose deafness over the potential loss of their child. A unique, life changing and potentially very profitable product.
But it seems to have stifled. CE marked Nov 19 and trials completed Nov 20. A distributor was signed a year ago, so what's the hold up - why no 'coming soon at a paediatric ward near you soon' or huge medical/general press marketing?
Make 'em hungry for it - "when can I get one??" "Gimme, gimme" " I want 10!" You get the idea.....
Ahhh those halcyon days of last May, such promise.....
https://www.google.com/amp/s/www.proactiveinvestors.co.uk/companies/amp/news/920677
Interesting interview article in today's Financial Mail with the boss of Morse Club commenting on the FCA, CMCs and the need for sub prime lending, including his own past experience.
Morse club are small loan sub prime lender whose rep APR is 498% - 10 times that of Amigo but seem to have a kept the FCA and CMCs at arm's length so far. Worth a read.
https://www.thisismoney.co.uk/money/markets/article-9607587/Morses-Club-boss-slams-City-watchdog-doorstep-loans.html
Thanks for the replies.
Just have to keep my fingers crossed a bit longer then, even tho' they've started to go green from being crossed for so long. Lol.
It's been nearly 10mths since we applied and over 5mths since we got 'permission' to start restricted sales in the USA while waiting for full EUA accreditation. I was wondering if this pre-emption action has meant that this temporary go ahead has diverted the FDA's gaze and they have moved us from the 'urgent' pile to the 'get round to it when we can' pile 'cos it takes the pressure off?
Just the meandering thought of a frustrated investor..... :S
2nd RNS now out confirming shares to remain suspended
"CASH IS KING"
Johnny or Pat??
Sorry CMM should read CMC.. doh!